Table 1. Clinical Characteristics by Recurrence

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Overall (n=100) | No Recurrence (n=86) | Recurrence (n=14) | *p*\* |
| Sex (% male) | 66% | 63% | 86% | 0.13 |
| Age (yrs) | 62 ± 11 | 62 ± 11 | 62 ± 11 | 0.92 |
| BSA (m2) | 1.98 ± 0.25 | 1.96 ± 0.25 | 2.06 ± 0.24 | 0.18 |
| LVEF (%) | 60 ± 7 | 61 ± 6 | 56 ± 14 | 0.41 |
| LA size (cm) | 3.8 ± 0.7 | 3.8 ± 0.7 | 4.1 ± 0.7 | 0.15 |
| LAVI (ml/m2) | 25.3 ± 8.0 | 24.8 ± 8.0 | 29.8 ± 7.5 | 0.29 |
| CHA2DS2-VASc | 1.9 ± 1.3 | 1.9 ± 1.3 | 1.9 ± 1.2 | 0.74 |
| HTN | 53% | 50% | 71% | 0.16 |
| Vascular Disease | 15% | 14% | 21% | 0.44 |
| DM | 11% | 13% | 0% | 0.35 |
| CHF | 7% | 6% | 14% | 0.25 |
| Stroke/TIA | 5% | 5% | 7% | 0.54 |
| AV nodal blocker | 66% | 66% | 64% | 1 |
|  Beta blocker | 63% | 63% | 64% | 1 |
|  CCB | 4% | 5% | 0% | 1 |
| Anti-arrhythmic | 75% | 77% | 64% | 0.33 |
|  Propafenone | 5% | 5% | 7% | 0.54 |
|  Flecainide | 5% | 6% | 0% | 1 |
|  Sotalol | 4% | 5% | 0% | 1 |
|  Amiodarone | 4% | 3% | 7% | 0.46 |
|  Dronedarone | 57% | 58% | 50% | 0.58 |

\**p* values for comparisons between “No Recurrence” and “Recurrence” groups

*Mean ± 1SD, LA size missing 14 values, normality SW, cat Fisher exact, BSA+LA size t test, age+LVEF+CHADS MWU*

Table 2. Ablation Characteristics by Recurrence

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Overall (n=100) | No Recurrence (n=86) | Recurrence (n=14) | *p*\* |
| Lesion Count | 147 ± 44 | 146 ± 42 | 154 ± 52 | 0.64 |
| Mean Excursion† (mm) | 0.99 ± 0.16 | 0.98 ± 0.17 | 1.08 ± 0.13 | 0.01 |
| Max Excursion† (mm) | 2.84 ± 0.40 | 2.80 ± 0.40 | 3.07 ± 0.38 | 0.03 |
| FTI† (gs) | 342 ± 75 | 346 ± 76 | 317 ± 71 | 0.18 |
| Lesion Duration† (s) | 17.6 ± 2.2 | 17.7 ± 2.2 | 17.2 ± 2.0 | 0.53 |
| Average Force† (g) | 19.4 ± 3.2 | 19.6 ± 3.2 | 18.4 ± 3.2 | 0.18 |
| STD Force† (g) | 6.26 ± 1.16 | 6.30 ± 1.09 | 5.96 ± 1.55 | 0.14 |
| Base Impedance† (ohms) | 122 ± 11 | 122 ± 12 | 118 ± 7 | 0.17 |
| Impedance Decline† (ohms) | 9.4 ± 2.1 | 9.6 ± 2.0 | 8.6 ± 2.0 | 0.17 |
| % Impedance Decline† | 7.6 ± 1.5% | 7.6 ± 1.4% | 7.1 ± 1.6% | 0.37 |
| Average Power† (W) | 31.2 ± 2.2 | 31.0 ± 2.2 | 32.0 ± 2.1 | 0.16 |
| RF time (min) | 69 ± 17 | 69 ± 17 | 69 ± 21 | 0.95 |
| % Interlesion distance >6mm† | 47 ± 9% | 46 ± 8% | 53 ± 9% | 0.01 |
| Number of PVs | 4.0 ± 0.6 | 4.1 ± 0.6 | 3.9 ± 0.5 | 0.22 |

\**p* values for comparisons between “No Recurrence” and “Recurrence” groups

†For a given patient, ablation parameters for all VisiTag lesions were averaged to form composite measures for each parameter

Table 3: Logistic Regression to Predict Recurrence

|  |
| --- |
| Logistic Regressions |
| Variable | Coefficient (β) | SE | Wald (χ2) | *p* value | Odds Ratio | 95% CI |
| Lesion Count | 0.00 | 0.01 | 0.42 | 0.52 | 1.00 | 0.99-1.02 |
| Mean Excursion | 3.37 | 1.71 | 3.89 | 0.049 | 28.94 | 1.02-819.17 |
| Max Excursion | 1.64 | 0.74 | 4.92 | 0.03 | 5.15 | 1.21-21.90 |
| FTI | -0.01 | 0.00 | 1.73 | 0.19 | 0.99 | 0.99-1.00 |
| Lesion Duration | -0.11 | 0.14 | 0.57 | 0.45 | 0.90 | 0.68-1.18 |
| Average Force | -0.13 | 0.10 | 1.73 | 0.19 | 0.88 | 0.72-1.07 |
| STD Force | -0.28 | 0.28 | 1.05 | 0.30 | 0.75 | 0.44-1.29 |
| Base Impedance | -0.04 | 0.03 | 1.83 | 0.18 | 0.96 | 0.91-1.02 |
| Impedance Decline | -0.27 | 0.16 | 2.77 | 0.10 | 0.76 | 0.56-1.05 |
| % Impedance Decline | -0.25 | 0.21 | 1.42 | 0.23 | 0.78 | 0.52-1.18 |
| Average Power | 0.19 | 0.13 | 2.15 | 0.14 | 1.21 | 0.94-1.56 |
| RF time | 0.00 | 0.02 | 0.01 | 0.94 | 1.00 | 0.97-1.04 |
| % Interlesion distance >6mm | 0.12 | 0.04 | 7.72 | 0.01 | 1.12 | 1.04-1.22 |
| Number of PVs | -0.71 | 0.57 | 1.56 | 0.21 | 0.49 | 0.16-1.49 |
| Sex (male) | 1.27 | 0.80 | 2.54 | 0.11 | 3.56 | 0.75-16.91 |
| Age | 0.01 | 0.03 | 0.06 | 0.81 | 1.01 | 0.96-1.06 |
| BSA | 1.48 | 1.13 | 1.70 | 0.19 | 4.39 | 0.48-40.49 |
| LVEF | -0.07 | 0.03 | 4.29 | 0.04 | 0.93 | 0.87-1.00 |
| LA size | 0.73 | 0.50 | 2.16 | 0.14 | 2.07 | 0.78-5.48 |
| LAVI (ml/m2) | 0.08 | 0.07 | 1.31 | 0.25 | 1.08 | 0.94-1.24 |
| CHA2DS2-VASc | 0.03 | 0.22 | 0.02 | 0.88 | 1.04 | 0.67-1.61 |
| HTN | 0.92 | 0.63 | 2.12 | 0.15 | 2.50 | 0.73-8.59 |
| Vascular Disease | 0.52 | 0.72 | 0.52 | 0.47 | 1.68 | 0.41-6.92 |
|  |  |  |  |  |  |  |
| CHF | 0.99 | 0.89 | 1.24 | 0.27 | 2.70 | 0.47-15.51 |
| Stroke/TIA | 0.46 | 1.16 | 0.15 | 0.69 | 1.58 | 0.16-15.23 |

Table S1. Clinical Characteristics by Catheter Stability

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Overall (n=100) | High Stability (n=50) | Low Stability (n=50) | *p*\* |
| Sex (% male) | 66% | 60% | 72% | 0.29 |
| Age (yrs) | 62 ± 11 | 62 ± 12 | 62 ± 10 | 0.59 |
| BSA (m2) | 1.98 ± 0.25 | 1.92 ± .25 | 2.04 ± 0.25 | 0.02 |
| Height (cm) | 173 ± 10 | 173 ± 10 | 174 ± 10 | 0.55 |
| Weight (kg) | 84 ± 20 | 79 ± 18 | 90 ± 20 | <0.01 |
| LVEF (%) | 60 ± 7 | 61 ± 7 | 60 ± 8 | 0.64 |
| LA size (cm) | 3.8 ± 0.7 | 3.7 ± 0.7 | 4.0 ± 0.6 | 0.045 |
| LAVI (ml/m2) | 25.3 ± 8.0 | 23.1 ± 7.1 | 28.2 ± 8.4 | 0.04 |
| CHA2DS2-VASc | 1.9 ± 1.3 | 1.8 ± 1.2 | 2.0 ± 1.4 | 0.55 |
| HTN | 53% | 48% | 58% | 0.42 |
| Vascular Disease | 15% | 14% | 16% | 1 |
| DM | 11% | 8% | 14% | 0.52 |
| CHF | 7% | 0% | 14% | 0.01 |
| Stroke/TIA | 5% | 4% | 6% | 1 |

High Stability: max excursion <2.81mm

Low Stability: max excursion >2.81mm

\**p* values for comparisons between “High Stability” and “Low Stability” groups

Table S2. Logistic Regression to Predict Catheter Stability (max excursion >2.81mm)

|  |
| --- |
| Univariate Logistic Regressions |
| Variable | Coefficient (β) | SE | Wald (χ2) | *p* value | Odds Ratio | 95% CI |
| Sex (male) | 0.54 | 0.43 | 1.59 | 0.21 | 1.71 | 0.74-3.96 |
| Age | 0.00 | 0.02 | 0.01 | 0.94 | 1.00 | 0.96-1.04 |
| BSA | 2.03 | 0.88 | 5.35 | 0.02 | 7.59 | 1.36-42.28 |
| Height | 0.01 | 0.02 | 0.36 | 0.55 | 1.01 | 0.97-1.05 |
| Weight | 0.03 | 0.01 | 7.12 | 0.01 | 1.03 | 1.01-1.06 |
| LVEF | -0.02 | 0.03 | 0.54 | 0.46 | 0.98 | 0.93-1.04 |
| LA size | 0.68 | 0.34 | 3.94 | 0.047 | 1.98 | 1.01-3.87 |
| LAVI (ml/m2) | 0.09 | 0.04 | 4.17 | 0.04 | 1.09 | 1.00-1.18 |
| CHA2DS2-VASc | 0.10 | 0.16 | 0.39 | 0.53 | 1.10 | 0.81-1.50 |
| HTN | 0.40 | 0.40 | 1.00 | 0.32 | 1.50 | 0.68-3.29 |
| Vascular Disease | 0.16 | 0.56 | 0.08 | 0.78 | 1.17 | 0.39-3.52 |
| DM | 0.63 | 0.66 | 0.90 | 0.34 | 1.87 | 0.51-6.85 |
| Stroke/TIA | 0.43 | 0.94 | 0.21 | 0.65 | 1.53 | 0.25-9.59 |
| Operator |  |  |  |  |  |  |
|  1 | 0.54 | 0.47 | 1.32 | 0.25 | 1.71 | 0.68-4.30 |
|  2 | 0.55 | 0.53 | 1.07 | 0.30 | 1.73 | 0.61-4.91 |
|  3 | 1.15 | 0.57 | 4.06 | 0.04 | 3.16 | 1.03-9.69 |
|  4 | -1.51 | 0.45 | 11.48 | <0.01 | 0.22 | 0.09-0.53 |

\*Odds ratio for decreased catheter stability

Table S3. Ablation Parameters by Catheter Spatial Stability

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Overall (n=100) | High Stability(n=50) | Low Stability (n=50) | *p*\* |
| Lesion Count | 147 ± 44 | 134 ± 41 | 161 ± 43 | <0.001 |
| Mean Excursion† (mm) | 0.99 ± 0.16 | 0.89 ± 0.10 | 1.10 ± 0.14 | <0.001 |
| Max Excursion† (mm) | 2.84 ± 0.40 | 2.52 ± 0.21 | 3.16 ± 0.27 | <0.001 |
| FTI† (gs) | 342 ± 75 | 353 ± 78 | 331 ± 72 | 0.17 |
| Lesion Duration† (s) | 17.6 ± 2.2 | 18.2 ± 2.3 | 17.1 ± 1.9 | 0.01 |
| Average Force† (g) | 19.4 ± 3.2 | 19.3 ± 2.8 | 19.6 ± 3.6 | 0.88 |
| STD Force† (g) | 6.26 ± 1.16 | 6.27 ± 1.08 | 6.25 ± 1.25 | 0.54 |
| Base Impedance† (ohms) | 122 ± 11 | 121 ± 12 | 122 ± 10 | 0.77 |
| Impedance Decline† (ohms) | 9.4 ± 2.1 | 9.4 ± 1.7 | 9.5 ± 2.4 | 0.86 |
| % Impedance Decline | 7.6 ± 1.5% | 7.6 ± 1.1% | 7.6 ± 1.7% | 0.99 |
| Average Power† (W) | 31.2 ± 2.2 | 30.6 ± 2.0 | 31.7 ± 2.3 | 0.04 |
| RF time (min) | 69 ± 17 | 66 ± 19 | 71 ± 16 | 0.29 |